The History and Efficacy of Intravitreal Injection of Pegaptanib in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion; The Need for Special Attention
We have read a recent article about intravitreal pharmacotherapy for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO) with great interest. You have mentioned that few studies have evaluated the efficacy of pegaptanib in ocular diseases; thus, discussing this the Food and Drug Administration (FDA)-approved drug is necessary.
Anti-VEGF therapy is a critical and potent approach for the management of macular edema. Anti-VEGF agents neither cause ruined alterations as lasers do, nor induce cataract formation as steroids do.
Al-Latayfeh M, Silva PS, Sun JK, Aiello LP. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med. 2012;2(6):a006411. doi:10.1101/cshperspect.a006411.
Lloyd R, Harris J, Wadhwa S, Chambers W. Food and Drug Administration approval process for ophthalmic drugs in the US. Curr Opin Ophthalmol. 2008;19(3):190-194. doi:10.1097/ICU.0b013e3282f97fa1.
Kimoto K, Kubota T. Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol. 2012;2012:852183. doi:10.1155/2012/852183.
Vinores SA. Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine. 2006;1(3):263-268.
Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816. doi:10.1056/NEJMoa042760.
Pozarowska D, Pozarowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol. 2016;41(3):311-316. doi:10.5114/ceji.2016.63132.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Medical Reviews is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.